nimacimab
nimacimab: sourced relationships with 1 company · 1 clinical trial tracked.
nimacimab evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect nimacimab to SKYE; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could nimacimab → SKYE affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Skye Bioscience, Inc. (SKYE) | Phase 2 |
Clinical Trial Registry Records (1)
A Phase 2 Study of QW Nimacimab Injection, Compared to Placebo Injection and QW Weekly Nimacimab Injection Co-administered With Semaglutide in Participants Who Are Overweight or Obese
Primary endpoint: Percent change in body weight (main study)
InterventionalRandomizedquadruple136 targetStarted 2024-08Completion 2027-0216 sites · United StatesSkye Bioscience, Inc.
Frequently asked questions
Which companies have sourced relationships with nimacimab?
nimacimab has dated SEC/FDA relationship records for Skye Bioscience, Inc..
How many clinical trials involve nimacimab?
BioSniper tracks 1 clinical trial involving nimacimab.